The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)
about
Omega 3 fatty acids for preventing or slowing the progression of age-related macular degenerationAge-related Eye Disease Study 2: perspectives, recommendations, and unanswered questionsMacular xanthophylls, lipoprotein-related genes, and age-related macular degenerationBlue-light reflectance imaging of macular pigment in infants and children.Present and possible therapies for age-related macular degeneration.Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5.European survey on the opinion and use of micronutrition in age-related macular degeneration: 10 years on from the Age-Related Eye Disease StudyEffect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial.Aspirin use and risk of age-related macular degeneration: a meta-analysisLong term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.Is aspirin use associated with age-related macular degeneration? A meta-analysis.Potential role of lampalizumab for treatment of geographic atrophy.Comparison of Mouse and Human Retinal Pigment Epithelium Gene Expression Profiles: Potential Implications for Age-Related Macular Degeneration.Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenationThe Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8Perspective: A Critical Look at the Ancillary Age-Related Eye Disease Study 2: Nutrition and Cognitive Function Results in Older Individuals with Age-Related Macular Degeneration.Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.Botanical compounds: effects on major eye diseasesMethods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2)The role of lutein in eye-related diseaseIdentification of a rare coding variant in complement 3 associated with age-related macular degenerationQuantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography.Genetic evidence for role of carotenoids in age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS).Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) studyPersonalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina.Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment.Nutritional supplements in age-related macular degeneration.An Evidence-Based Systematic Review of Lutein by the Natural Standard Research Collaboration.Optical Coherence Tomography Predictors of Risk for Progression to Non-Neovascular Atrophic Age-Related Macular Degeneration.Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.Risk of Deficiency in Multiple Concurrent Micronutrients in Children and Adults in the United States.Nutrition, Genes, and Age-Related Macular Degeneration: What Have We Learned from the Trials?Bivariate Analysis of Age-Related Macular Degeneration Progression Using Genetic Risk Scores.Dye solutions based on lutein and zeaxanthin: in vitro and in vivo analysis of ocular toxicity profiles.The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration.
P2860
Q24186584-C2F3DB7F-08CB-408A-9010-515B682F1CB1Q26823002-7C76D742-AE48-4EDC-BE70-35564F4DE461Q28240096-01037E33-ABE9-4DB7-9ADF-EB58DE360182Q30540581-19466913-74CA-42E7-8A66-1682DFEF0F98Q33562731-67170150-A38B-4FB8-B6F3-52E66DD33C08Q33717538-28A80EE5-11AF-4098-8B22-BEC1AB292281Q34353014-202CFD73-F257-4F27-BC83-5C8806F5F3C4Q34490891-E8159CED-C880-4434-8684-B32E8E80BEEFQ34630065-C25D8B12-29F2-453D-9945-AB56B4B325B2Q34733171-324F5C79-CBD2-48AF-A6F2-952E48F027B0Q35491511-0FC23D93-0EA6-4F34-B9C9-1E635FA89F30Q35746909-A1C73F68-2FC0-4B62-9526-581A94ADC08DQ35827351-44AC7777-453C-4ED7-81AA-7E6C0DE0A928Q36257030-97C02FDC-1EC5-4F89-B6F2-6582E33C1C5CQ36315753-3128454E-6EE9-4F38-8054-B6EDA6BF4D1CQ36374238-CCE2F4FD-BCCE-417B-A5A2-D7551A83170FQ36678453-052E5985-2F1D-44B2-A91A-13EE4DEBDFB1Q36730429-5E01EA70-56DC-4191-8168-55DF822201F3Q36890365-B2DE35FA-5EAC-4D87-B30F-85F2E971E35AQ36926292-EB009BCF-1F48-4A39-A776-B4D0EC555487Q36988482-BDF925B5-6D13-4BB3-B9F4-7B5184D88EE4Q36996217-4B0B23E2-6816-483B-8C62-211C56BD77A3Q37002600-5E08AFD2-F16D-496A-A697-23BA296DA18EQ37265929-A3C28BE9-BDCE-40A3-9702-7567A74D91AEQ37513827-F93F1FFA-CEED-4F2D-9D47-46D9FDF8E289Q37537304-BA9645B3-C580-4583-A3AC-4B6B0FE1B34DQ37570185-B19AA8FE-548B-4CF6-AC8A-A6D3C5565E5AQ37627442-3B7635F2-2349-4A2E-93FA-46FF08150658Q37645117-A64E4D80-5BBD-4146-9771-AE1840F211C6Q38192127-D3BF2E50-D0AA-4EEF-9059-03A085E2149FQ38317289-606364B8-D277-49A2-A884-D1320ECF2D71Q38330232-ECB14293-41F6-416F-8995-D8EA500E9ED3Q38605292-143B739D-956C-4120-8383-A2486F5E8D32Q38611218-AB1F9D11-4363-4E80-90B6-1621DF6C53E9Q38653249-CC961AE5-0B1D-4FCF-87B2-1F4E87BAA834Q38696053-3B45D416-44BE-47A4-9D11-E329B16ACC7BQ38800270-CA4613B4-9F43-4BEB-AA40-9D425E95E03BQ38877436-767B8D48-0AA6-4586-B0EC-9A270AAC1667Q38963195-8E48248E-FF59-487F-A131-1099D4A79613Q39092535-4090A1A4-5207-404C-90E4-CFE853FF7CB1
P2860
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@ast
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@en
type
label
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@ast
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@en
prefLabel
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@ast
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@en
P2093
P2860
P1433
P1476
The Age-Related Eye Disease St ...... stics (AREDS2 report number 1)
@en
P2093
AREDS2 Research Group
Amitha Domalpally
Frederick L Ferris
John Paul SanGiovanni
Robert Sperduto
Ronald Danis
Traci Clemons
Wendy McBee
P2860
P304
P356
10.1016/J.OPHTHA.2012.05.027
P50
P577
2012-07-26T00:00:00Z